What a Real Peptide COA Looks Like: Reading Purity Data

A Certificate of Analysis (COA) is a document that reports the results of analytical testing performed on a specific batch — or lot — of material. In research chemistry, it is the primary record connecting a physical sample to its claimed identity and purity. For laboratory researchers working with synthetic peptides, knowing how to read a COA is as fundamental as knowing how to read a chromatogram: it is the difference between trusting a label and verifying what is in the vial.

This guide explains what a peptide COA contains, how its key sections are generated, and what to look for when evaluating one.

What a COA Is — and Is Not

A COA is a batch-specific test report. It states what was tested, which methods were used, what the results were, and whether the batch met the supplier's stated specifications. It is not a marketing document, and it is not interchangeable between batches: a COA for lot A says nothing about lot B.

A complete peptide COA typically includes:

• Identificazione del prodotto — compound name, catalog number, lot/batch number
• Test date and retest date — when the analysis was performed and until when the results are considered valid
• Appearance — a visual description of the material (e.g., white lyophilized powder)
• Purity by HPLC — the headline number, usually expressed as a percentage
• Identity by mass spectrometry — confirmation that the molecular mass matches the expected sequence
• The testing laboratory's name — who performed the analysis
• A signature or approval — from the analyst or quality reviewer

Every element matters, but purity and identity are the two pillars. Everything else is supporting evidence.

Purity by HPLC: The Headline Number

When a COA states "Purity: 99.2%," that number almost always comes from reversed-phase high-performance liquid chromatography (RP-HPLC) with UV detection. This is the standard analytical method for peptide purity assessment in both research and pharmaceutical settings (Mant & Hodges, 1996).

Come funziona

The peptide sample is dissolved and injected onto a chromatography column packed with a hydrophobic stationary phase (typically C18 silica). A mobile-phase gradient — usually water and acetonitrile, each containing a small amount of trifluoroacetic acid (TFA) — is pumped through the column. Peptides and impurities partition between the stationary and mobile phases based on their hydrophobicity, eluting at different times. A UV detector, most commonly set at 214 nm where the peptide bond absorbs strongly, records each eluting component as a peak on a chromatogram.

How purity is calculated

Purity is calculated by peak area normalization: the area under the main product peak is divided by the total area of all detected peaks, then multiplied by 100.

Purity (%) = (main peak area ÷ total peak area) × 100

A chromatogram showing one dominant peak at 99.2% area with a few small impurity peaks totaling 0.8% is a typical result for a high-quality synthetic peptide.

What the impurities are

The minor peaks represent synthesis-related impurities common to solid-phase peptide synthesis (SPPS):

• Deletion sequences — peptides missing one amino acid, a common SPPS byproduct
• Truncated sequences — chains terminated early during synthesis
• Oxidation products — e.g., methionine or tryptophan oxidation during handling
• Deamidation products — asparagine or glutamine conversion, which changes retention time slightly
• Racemized or isomeric variants — stereochemical impurities that may co-elute or separate depending on conditions

A good COA shows the chromatogram itself, not just the number. The visual record lets a trained reader assess peak shape, baseline quality, and whether the integration looks reasonable.

What "≥99% purity" means

The "≥99%" threshold commonly seen on research peptide COAs means the main product peak accounts for at least 99% of the total UV-detectable peak area under the stated HPLC conditions. It is a strong result — but it is method-dependent. Purity values are only comparable when measured under equivalent chromatographic conditions, because different gradients, columns, or detection wavelengths can change which impurities are resolved and detected.

Note that area normalization assumes all components have similar UV response factors. This is a reasonable approximation for peptide-related impurities (which share the same chromophores), but it is an approximation — one reason identity confirmation by a second, orthogonal method matters.

Identity by Mass Spectrometry: Confirming What It Is

HPLC tells you how pure a sample is; it does not tell you what the main peak actually is. Two different peptides can have similar retention times. That is why identity confirmation by mass spectrometry (MS) is the second pillar of a peptide COA.

The standard approach is electrospray ionization (ESI) or matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, which measures the molecular mass of the intact peptide. The measured mass is compared against the theoretical mass calculated from the amino acid sequence. Agreement within the instrument's mass accuracy — typically reported in parts per million (ppm) — confirms the identity.

For example, a peptide with a theoretical monoisotopic mass of 3,411.5 Da measured at 3,411.6 Da is consistent with the expected sequence. A discrepancy of several daltons would indicate a problem: a missing residue, an unexpected modification, or the wrong compound entirely.

High-resolution MS/MS fragmentation can go further, confirming the actual amino acid sequence residue by residue — the basis of peptide mapping used in therapeutic protein characterization (PMID 41155256). For research peptide COAs, intact mass confirmation is the usual standard, and it is sufficient when paired with HPLC purity data.

The key point: purity without identity is meaningless, and identity without purity is incomplete. A COA should provide both.

Batch Numbers and Traceability

The lot or batch number is what ties the COA to the physical vial. Without it, a COA is just a document — it could describe any batch, or no batch at all.

When evaluating a COA, check that:

• The lot number is printed on the COA e on the product vial or packaging
• The compound name and catalog number match what was ordered
• The test date is reasonably recent relative to the retest date
• The COA is specific to the lot in hand, not a generic or representative document

Retest dates reflect the period during which the supplier stands behind the analytical results, typically 12–24 months for lyophilized peptides stored as directed. They are not expiration dates in the pharmaceutical sense, but they indicate the window of the supplier's analytical warranty.

Sterility and Other Testing

Depending on the supplier and the intended research context, a COA may also report:

• Sterility testing (e.g., USP <71>) — confirming the absence of viable microorganisms
• Endotoxin testing (e.g., USP <85>, Limulus amebocyte lysate assay) — measuring bacterial endotoxin levels
• Residual solvents — from synthesis and purification steps
• Counterion content — TFA is the standard counterion in SPPS-derived peptides; some suppliers report it

Testing panels vary between suppliers. What matters is that the COA states clearly which tests were performed and which were not — a COA that is transparent about its scope is more trustworthy than one that implies comprehensive testing without evidence.

Third-Party vs. In-House Testing

A COA is only as credible as the laboratory behind it. There are two models:

In-house testing means the supplier analyzes its own products. This is common and not inherently unreliable, but it carries an obvious conflict of interest: the party selling the material is also the party certifying it.

Third-party testing means an independent analytical laboratory — one with no financial stake in the sale — performs the analysis and issues the COA. The independence removes the conflict of interest and is widely regarded as the stronger standard.

When reading a COA, look for the testing laboratory's name. A COA from a named, independent lab (for example, a dedicated peptide analytical service) carries more weight than an unsigned document from an unnamed source. Some suppliers publish COAs from multiple independent labs, which is an additional credibility signal.

Red Flags in Questionable COAs

Not all COAs deserve equal trust. Warning signs include:

1. No chromatogram image. A purity number without the underlying chromatogram cannot be independently assessed.
2. No mass spectrometry data. Identity confirmation is a basic expectation; its absence is a gap.
3. No lot number — or a lot number that does not match the vial.
4. No testing laboratory named. An anonymous COA is unverifiable.
5. Identical COAs across different products. Real analytical data varies between compounds and batches; copy-pasted documents are a serious red flag.
6. No test date or retest date. Undated results have no defined validity window.
7. Unrealistic claims. A COA claiming 100.0% purity should be viewed skeptically — analytical methods have detection limits, and genuine results are rarely absolute.

Why This Matters for Research

In laboratory research, the identity and purity of starting materials directly affect the validity of experimental results. An impurity profile that is unknown or misrepresented can confound assays, shift dose-response relationships, or produce irreproducible data. The COA is the researcher's first line of defense: it is the documented evidence that the material in the vial is what the label claims, at the purity claimed.

Researchers who work with synthetic peptides routinely request COAs before ordering, compare chromatograms between suppliers, and archive COAs alongside their experimental records. It is standard good practice in any analytical workflow.

A Note on NUPEPS PEPTIDES

NUPEPS PEPTIDES publishes third-party COAs for every lot it supplies, and maintains a public COA library researchers can consult before ordering. The company's testing panel covers purity, quantity, and sterility for its research reference materials.

Domande frequenti

What does "≥99% purity" on a COA actually mean?

It means the main product peak accounts for at least 99% of the total UV-detectable peak area in the HPLC analysis, measured under the conditions stated on the COA. It is a strong result, but it is method-dependent — purity values should only be compared between analyses performed under equivalent conditions.

Can a COA's HPLC result be misleading?

The number alone can be. Purity by area normalization depends on the chromatographic method: a short gradient or a low-resolution column may fail to separate impurities, inflating the apparent purity. This is why a credible COA includes the actual chromatogram and the method parameters, not just the final percentage.

What is the difference between in-house and third-party COAs?

In-house COAs are issued by the supplier's own laboratory; third-party COAs come from an independent analytical lab with no stake in the sale. Third-party testing removes the conflict of interest inherent in self-certification and is generally considered the stronger standard.

Why does a COA include mass spectrometry data?

HPLC measures purity but cannot confirm identity — different compounds can share retention times. Mass spectrometry confirms the molecular mass matches the expected amino acid sequence, verifying that the pure material is actually the correct peptide.

What should I check first when reading a peptide COA?

Start with three things: (1) does the lot number match your vial, (2) is there an actual HPLC chromatogram with a stated purity percentage, and (3) is there mass spectrometry data confirming identity. Then check the testing lab's name and the test date.

Do COAs expire?

COAs carry a retest date rather than an expiration date — typically 12–24 months from testing for lyophilized peptides. The retest date marks the period during which the supplier stands behind the analytical results, assuming the material was stored as directed.

References

1. Mant CT, Hodges RS. Analysis of peptides by high performance liquid chromatography. Methods Enzymol. 1996;271:3–50.
2. Guo D, Mant CT, Taneja AK, Parker JMR, Hodges RS. Prediction of peptide retention times in reversed-phase high-performance liquid chromatography. J Chromatogr. 1986;359:499–517. doi:10.1016/S0021-9673(01)94598-4
3. Peptide mapping for sequence confirmation of therapeutic proteins and recombinant vaccine antigens by high-resolution mass spectrometry. Int J Mol Sci. 2025. PMID: 41155256
4. United States Pharmacopeia, General Chapter <621> — Chromatography. USP–NF.